Diseases and Conditions

The nonclinical drug candidates that Akros Pharma takes into clinical development come out of the research conducted by the Central Pharmaceutical Research Institute (CPRI) of JT Pharmaceuticals in Osaka, Japan. The current development focus for Akros reflects the research focus at CPRI.

Currently, CPRI and Akros are working to develop new therapeutics for the following disease states:

Code Potential Indication Dosage form Mechanism Stage
JTZ-951
Anemia associated with
chronic kidney disease
Oral HIF-PHD inhibitor Increases red blood cells by stimulating production of erythropoietin, an erythropoiesis-stimulating hormone, via inhibition of HIF-PHD. Phase1
JTE-051

Autoimmune diseases
Allergic diseases
Oral
Interleukin-2 inducible
T cell kinase inhibitor
Suppresses overactive immune response via inhibition of the signal to activate T cells related to immune response. Phase2
JTT-251
Type 2 diabetes mellitus
Oral PDHK inhibitor Decreases blood glucose by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism. Phase1
JTE-451

Autoimmune diseases
Allergic diseases
Oral
RORγ antagonist
Suppresses overactive immune response via inhibition of RORγ related to Th17 activation. Phase1
Clinical trial phase presented above is based on the first dose.


©2007 Akros Pharma Inc. All rights reserved.